Skip to main content

Table 1 Baseline Characteristics

From: The clinical impact of Lumacaftor-Ivacaftor on structural lung disease and lung function in children aged 6–11 with cystic fibrosis in a real-world setting

 

Participants (n = 71)

Variable

n

Mean

Std Deviation

Age (years)

71

8.67

1.777

Sex

   

Female, n(%)

71

36

50.7%

Height z-score

71

-0.13

1.015

Weight z-score

71

-0.15

0.889

BMI z-score

71

0.01

0.795

LCI2.5

28

9.15

2.412

ppFEV1

71

92.58

18.769

FEV1 Category

   

< 40

71

1

1.4%

40-<70

 

6

8.5%

≥ 70

 

64

90.1%

Hospitalisations per annum

71

1.18

0.198

Pseudomonas status

   

Clear

71

65

91.5%

Intermittent

 

5

7.0%

Chronic

 

1

1.4%

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us